Search

Your search keyword '"Giuseppe Viscardi"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Giuseppe Viscardi" Remove constraint Author: "Giuseppe Viscardi" Topic medicine.disease Remove constraint Topic: medicine.disease
30 results on '"Giuseppe Viscardi"'

Search Results

1. TERAVOLT: Thoracic Cancers International COVID-19 Collaboration

2. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology

3. Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma

4. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy

5. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program

6. Chemotherapy-induced bowel ischemia: diagnostic imaging overview

7. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers

8. Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system

9. How i treat malignant pleural mesothelioma

10. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: Young oncologists' perspective

11. P40.08 Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors

12. 1327P Impact of bone targeted agents (BTA) in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD(L)1 inhibitors (ICIs)

13. Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study

14. Epsilon: A prognostic score for immunotherapy in advanced non-small-cell lung cancer: A validation cohort

15. 184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs)

16. 1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)

17. Abstract 4480: Circulating and tumor associated neutrophil subtypes correlate with hyperprogressive disease (HPD) upon immunecheckpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC) patients (pts) and in vivo models

18. Efficacy and safety of immunotherapy in non-small cell lung cancer patients with poor performance status

19. Circulating and tumor-associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models

20. Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy

21. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer

22. HGF/MET and the Immune System: Relevance for Cancer Immunotherapy

23. Role and targeting of anaplastic lymphoma kinase in cancer

24. Clinical Approach: Recommendations for the Clinicians

25. Implication of the Hedgehog pathway in hepatocellular carcinoma

26. Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments

27. Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature

29. Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer

Catalog

Books, media, physical & digital resources